Interview: Jung Hyun Ho – Founder & CEO, Medytox – Korea
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
Medytox has successfully developed the fourth botulinum toxin type A product in the world, and today exports products to more than 60 countries including Japan, Thailand, India, and Brazil. Medytox has been making efforts to penetrate into the US and European market in the near future to show its presence as a leading global biopharmaceutical company.
Medytox is at the forefront of the Korean biopharmaceutical industry, thanks to its excellent R&D capabilities with top-teir biotechnologists, and to its state-of-the-art operations and production facilties. Moreover, Medytox is going to become a frontier in the field of biopharmaceuticals due to its passion and courage to embrace global challenges.
Contact Details
78, Gangni 1-gil, Ochang-eup, Cheongwon-gu,
Cheongju-si, Chungcheongbuk-do
Korea
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
The CEO of Mega Medical, a Korean medical equipment manufacturer specialized in the ENT area, discusses his firm’s recent expansion into the anti-obesity segment, their strategy for building a global…
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
Albert Liou discusses the success of the government’s investment in clinical trial infrastructure, which has triggered the rapid growth and advancement of the Korean clinical trial market and spurred innovation…
The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation. Where did your idea for starting Korea Pharma come from? I am a pharmacist…
Tom Roberts came to UCB Korea following a position at the company’s Japanese affiliate in late 2011. He describes the market conditions for UCB’s specialty products and emphasizes the importance…
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Chung Seung, Minister of Food and Drug Safety, discusses the latest improvements to Korea’s regulatory system and highlights vaccines, biosimilars and stem cell research as key components of the country’s…
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Janssen’s managing director in Korea discusses the groups long and significant commitment to R&D in the country, as well as some of the challenges that one of the most innovative…
The founder of MEDIPOST, the producer of the only approved allogenic stem cell product in the world, disucsses their development goals for the coming years and the potential for regenerative…
Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the…
After a lengthy career at Novartis, Angie Kim recently started working at BMS Korea to develop the affiliate. She discusses diversifying the company’s portfolio and their footprint in Korea as…
See our Cookie Privacy Policy Here
